Kazia Therapeutics Limited (KZIA)

Market Cap	16.73M
Revenue (ttm)	382
Net Income (ttm)	-10.70M
Shares Out	29.79M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,344,643
Open	0.520
Previous Close	0.502
Day's Range	0.510 - 0.647
52-Week Range	0.190 - 1.580
Beta	2.10
Analysts	Strong Buy
Price Target	2.00 (+256.13%)
Earnings Date	Oct 29, 2024

About KZIA

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA
• Website: https://www.kaziatherapeutics.com

Financial Performance

In 2023, Kazia Therapeutics's revenue was 555, a decrease of -94.45% compared to the previous year's 10,000. Losses were -20.47 million, -18.19% less than in 2022.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for KZIA stock is "Strong Buy" and the 12-month stock price forecast is $2.0.

Price Target

$2.0

(256.13% upside)

Analyst Consensus: Strong Buy